NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's Chief Financial Officer, Ian Somaiya, will engage in a virtual fireside chat on Monday, April 7, 2025, at 12:45 p.m. ET. Investors and interested parties can access the live webcast through the investor relations section at ir.newamsterdampharma.com, with an archived replay available afterward on the company's website.
NewAmsterdam Pharma (Nasdaq: NAMS), un'azienda biofarmaceutica in fase avanzata clinica focalizzata nello sviluppo di medicinali orali non statinici per pazienti affetti da malattie cardiovascolari con LDL-C elevato, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute.
Il Direttore Finanziario dell'azienda, Ian Somaiya, parteciperà a una chiacchierata virtuale lunedì 7 aprile 2025, alle 12:45 p.m. ET. Gli investitori e le parti interessate possono accedere alla diretta tramite la sezione delle relazioni con gli investitori su ir.newamsterdampharma.com, con una riproduzione archiviata disponibile successivamente sul sito web dell'azienda.
NewAmsterdam Pharma (Nasdaq: NAMS), una compañía biofarmacéutica en etapa avanzada centrada en el desarrollo de medicamentos orales no estatínicos para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Atención Médica de Needham.
El Director Financiero de la compañía, Ian Somaiya, participará en una charla virtual el lunes 7 de abril de 2025, a las 12:45 p.m. ET. Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de relaciones con inversores en ir.newamsterdampharma.com, con una repetición archivada disponible posteriormente en el sitio web de la compañía.
NewAmsterdam Pharma (Nasdaq: NAMS)는 LDL-C 수치가 높은 심혈관 질환 환자를 위한 경구 비스타틴 약물 개발에 주력하는 후기 단계 임상 생물 제약 회사로, 제24회 니드햄 가상 의료 회의에 참여한다고 발표했습니다.
회사의 최고 재무 책임자(CFO)인 Ian Somaiya는 2025년 4월 7일 월요일 오후 12시 45분 ET에 가상 대담에 참여할 예정입니다. 투자자 및 관심 있는 당사자는 ir.newamsterdampharma.com의 투자자 관계 섹션을 통해 실시간 웹캐스트에 액세스할 수 있으며, 이후 회사 웹사이트에서 아카이브된 재생을 이용할 수 있습니다.
NewAmsterdam Pharma (Nasdaq: NAMS), une entreprise biopharmaceutique en phase avancée se concentrant sur le développement de médicaments oraux non-statines pour les patients atteints de maladies cardiovasculaires avec un LDL-C élevé, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
Le Directeur Financier de l'entreprise, Ian Somaiya, participera à une discussion virtuelle le lundi 7 avril 2025, à 12h45 ET. Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la section des relations investisseurs sur ir.newamsterdampharma.com, avec une rediffusion archivée disponible par la suite sur le site web de l'entreprise.
NewAmsterdam Pharma (Nasdaq: NAMS), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Entwicklung von oralen, nicht-statinischen Medikamenten für Patienten mit Herz-Kreislauf-Erkrankungen und erhöhtem LDL-C konzentriert, hat seine Teilnahme an der 24. jährlichen virtuellen Needham Gesundheitskonferenz bekannt gegeben.
Der Finanzvorstand des Unternehmens, Ian Somaiya, wird am Montag, den 7. April 2025, um 12:45 Uhr ET, an einem virtuellen Gespräch teilnehmen. Investoren und Interessierte können über den Bereich Investor Relations auf ir.newamsterdampharma.com auf den Live-Webcast zugreifen, und eine archivierte Wiederholung wird später auf der Website des Unternehmens verfügbar sein.
- None.
- None.
NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a virtual fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 12:45 p.m. ET.
A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
jleady@spectrumscience.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ
When is NewAmsterdam Pharma (NAMS) presenting at the Needham Healthcare Conference 2025?
How can investors watch NewAmsterdam Pharma's (NAMS) Needham Conference presentation?
What type of medications is NewAmsterdam Pharma (NAMS) developing?
Who will represent NewAmsterdam Pharma (NAMS) at the 2025 Needham Healthcare Conference?
